-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-101 in Solid Tumor Drug Details: GSK-101 are under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GS-0201 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GS-0201 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GS-0201 in Solid Tumor Drug Details: Small molecule is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GS-0201 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GS-0201 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GS-0201 in Triple-Negative Breast Cancer (TNBC) Drug Details: Small...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GS-0201 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GS-0201 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GS-0201...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceralasertib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Pancreatic Cancer Drug Details: Ceralasertib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceralasertib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Solid Tumor Drug Details: Ceralasertib is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Serplulimab in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Serplulimab in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Serplulimab in Esophageal Cancer Drug Details: Serplulimab (Hansizhuang, Zerpidio) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Malignant Mesothelioma Drug Details: Rucaparib camsylate (Rubraca)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Adenocarcinoma Of The Gastroesophageal...